Mizolastine provides effective symptom relief in patients suffering from chronic idiopathic urticaria*1A randomized, comparative study versus loratadine in China

Abstract Rationale A two-center randomized, comparative study versus loratadine was conducted to examine the efficacy and safety of mizolastine in chronic idiopathic urticaria (CIU) compared with loratadine. Methods This trial followed GCP guidelines. 145 adult CIU patients completed mizolastine (M) 10mg (71/145) and loratadine (L) 10mg (74/145) once daily for 28 days. 9 patients withdrew or dropped out. The symptom relief was analysis according to symptom score reducing index came from patients' diary data. Adverse drug reaction (ADR) findings were completed by the information from inquiry, physical examination, laboratory tests (liver and renal function, blood and urine routine test) and ECG. A specialist on ECG was invited to join in this trial. Results The score decrease of wheal in M group was superior to that in L group (p Conclusions The results confirm that mizolastine is effective and well tolerated in CIU treatment. The efficacy of mizolastine is similar to loratadine. However, mizolastine provided greater improvement in wheal reducing than loratadine.